Genetic predictors for drug resistance in soft tissue sarcoma: A review of publications in 2004

Current Opinion in Oncology

Volumn 17, Issue 4, 2005, Pages 370-375

  Fayette, Jérôme ^a   Blay, Jean Yves ^b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b NONE

Author keywords

Apoptosis; Drug resistance; Gastrointestinal tumors; Genetic predictors; Multidrug resistance; Sarcoma; Translocations

Indexed keywords

FOLIC ACID; IMATINIB; MESSENGER RNA; METHOTREXATE; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P53; PROTEIN TYROSINE KINASE; SUNITINIB; SURVIVIN;

AMINO ACID SEQUENCE; APOPTOSIS; CANCER SURVIVAL; DNA REPAIR; DRUG RESISTANCE; GASTROINTESTINAL TUMOR; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOFT TISSUE SARCOMA; TUMOR CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 21344443685     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000166650.30793.f2     Document Type: Review

References (41)

1. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432:307-315. This is an excellent review about the mechanisms of apoptosis or of cell cycle arrest. A didactic description of the intrinsic and extrinsic apoptosis pathway is presented.
2. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995; 376:37-43.
3. Voorzanger-Rousselot N, Favrot M, Blay JY. Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood 1998; 92:3381-3387.
4. Thallinger C, Wolschek MF, Maierhofer H, et al. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. Clin Cancer Res 2004; 10:4185-4191. This article shows how a protein of the bcl2 family can mediate drug resistance and shows in vitro how an antisense strategy may reverse this phenomenon.
5. Kappler M, Kotzsch M, Bartel F, et al. Elevated expression level of survivin protein in soft-tissue sarcomas is a strong independent predictor of survival. Clin Cancer Res 2003; 9:1098-1104.
6. Davidovich IA, Levenson AS, Levenson Chernokhvostov VV. Overexpression of DcR1 and survivin in genetically modified cells with pleiotropic drug resistance. Cancer Lett 2004; 211:189-197.
7. Sherr CJ. Principles of tumor suppression. Cell 2004; 116:235-246. A fundamental review focusing on tumor suppressor genes and on p53, whose function is particularly detailed.
8. Magro PG, Russo AJ, Li WW, et al. p14ARF expression increases dihydrofolate reductase degradation and paradoxically results in resistance to folate antagonists in cells with nonfunctional p53. Cancer Res 2004; 64:4338-4345.
9. Huang HY, Illei PB, Zhao Z, et al. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 2005; 23:548-558. A study of 60 cases of Ewing sarcoma to establish the prognostic value of the combination of EWS-FLI1 gene fusion, p53 mutations, and p16/p14ARF deletion. Alterations in p53 or p16/p14ARF are found in 25% of Ewing sarcoma cases and define a subset with highly aggressive behavior and poor chemoresponse.
10. Pakos EE, Kyzas PA, Ioannidis JP. Prognostic significance of TP53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis. Clin Cancer Res 2004; 10:6208-6214. This meta-analysis shows that p53 status does not correlate with histologic response to chemotherapy in patients with osteosarcoma, whereas p53 gene alterations may be associated with decreased survival.
11. Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol 2000; 12:450-458.
12. Oda Y, Saito T, Tateishi N, et al. ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas. Int J Cancer 2005; 119: 854-862.
13. Cagliero E, Ferracini R, Morello E, et al. Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma. Oncol Rep 2004; 12:1023-1031.
14. Ifergan I, Meller I, Issakov J, et al. Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity. Cancer 2003; 98:1958-1966.
15. Gallego S, Llort A, Parareda A, et al. Expression of multidrug resistance-1 and multidrug resistance-associated protein genes in pediatric rhabdomyosarcoma. Oncol Rep 2004; 11:179-183.
16. Chano T, Mori K, Scotlandi K, et al. Differentially expressed genes in multidrug resistant variants of U-2 OS human osteosarcoma cells. Oncol Rep 2004; 11:1257-1253. With a differential display reverse-transcription polymerase chain reaction to parental and MDR variants of U-2 OS human osteosarcoma cells, the authors clarify the genes involved in the MDR cells and identify five candidate genes.
17. Bush JA, Li G. Cancer chemoresistance: the relationship between p53 and multidrug transporters. Int J Cancer 2002; 98:323-330.
18. Zhan M, Yu D, Liu J, et al. Transcriptional repression of protein kinase C{alpha} via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation. J Biol Chem 2005; 280:4825-4833. This article clearly demonstrates a linkage between p53, PKCα, and the multidrug resistance phenotype. This highlights the complexity of the mechanisms implicated in drug resistanc e.
19. Staibano S, Franco R, Tranfa F, et al. Orbital rhabdomyosarcoma: relationship between DMA ploidy, p53, bcl-2, MDR-1 and Ki67 (MIB1) expression and clinical behavior. Anticancer Res 2004; 24:249-257.
20. Berwick M, Matullo G, Song YS, et al. Association between aryl hydrocarbon receptor genotype and survival in soft tissue sarcoma. J Clin Oncol 2004; 22:3997-4001.
21. Koyama T, Suzuki H, Imakiire A, et al. Id3-mediated enhancement of cisplatin-induced apoptosis in a sarcoma cell line MG-63. Anticancer Res 2004; 24:1519-1524.
22. Oliveira AM, Fletcher CD. Molecular prognostication for soft tissue sarcomas: are we ready yet? J Clin Oncol 2004; 22:4031-4034.
23. Ladanyi M. Fusions of the SYT and SSX genes in synovial sarcoma. Oncogene 2001; 20:5755-5762.
24. Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 2002; 62:135-140.
25. Guillou L, Eienhattar J, Bonichon F, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 2004; 22:4040-4050. These two articles show the difficulty of validating molecular prognostic factors, even in an apparently homogenous cohort of diseases and patients, and the importance of validation series for these analysis.
26. Des Guetz G, Delattre O, Peters M, et al. Study of the prognostic value and chemosensitivity according to the type of translocation in synovial sarcoma [abstract]. Proc Am Soc Clin Oncol 2004; 22:abstract 9016.
27. Serra M, Reverter-Branchat G, Maurici D, et al. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol 2004; 15:151-160. This study shows that methotrexate resistance in osteosarcoma cells is related to several proteins, including dihydrofolate reductase and reduced folate carrier, regarding retinoblastoma gene status.
28. Hattinger CM, Reverter-Branchat G, Remondini D, et al. Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. Eur J Cell Biol 2003; 82:483-493.
29. Flintoff WP, Sadlish H, Gorlick R, et al. Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas. Biochim Biophys Acta 2004; 1690:110-117. Functionality of the reduced folate carrier is dependent on the level of expression but also on the sequence changes. Certain are responsible of a total inhibition of the intracellular methotrexate penetration.
30. Kaufman Y, Drori S, Cole PD, et al. Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia. Cancer 2004; 100:773-782.
31. Ochi K, Daigo Y, Katagiri T, et al. Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol 2004; 24:647-655. Expression profile analysis using cDNA microarray consisting of 23,040 genes allows the isolation of a set of 60 genes associated with drug resistance of osteosarcoma cells.
32. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22:3813-3825. A recent and detailed review on gastrointestinal tumors.
33. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21:4342-4349.
34. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004; 28:889-894.
35. Demetri GD, Desai J, Fletcher JA, et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) [abstract]. Proc Am Soc Clin Oncol 2004; 22:abstract 3001.
36. Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004; 64:5913-5919.
37. Tamborini E, Bonadiman L, Greco A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004; 127:294-299.
38. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003; 39:2006-2011.
39. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium study b2225. J Clin Oncol 2005; 23:866-873. The first example of efficiency of imatinib in sarcoma distinct from GIST showing that sensitivity to targeted therapies is related to the nature of the molecular alteration causing the neoplastic disease.
40. Went PT, Dirnhofer S, Bundi M, et al. Prevalence of KIT expression in human tumors. J Clin Oncol 2004; 22:4514-4522.
41. Duensing A, Medeiros F, McConarty B, et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 2004; 23:3999-4006.